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Abstract
New psychoactive substances continue to appear on the drug market. Until recently, new syn-
thetic opioids, which are among the most dangerous new psychoactive substances, primarily
encompassed analogs of the potent analgesic fentanyl. Lately, also other new synthetic opioids
have increasingly started to surface. This is the first report on the identification and full chemical
characterization of brorphine, a novel potent synthetic opioid with a piperidine benzimidazolone
structure. A powder, identified as brorphine, was obtained from a patient seeking medical help for
detoxification. Brorphine was also found in a serum sample of the patient. Liquid chromatography–
high-resolution mass spectrometry (LC–HRMS) identified an exact mass of m/z 400.1020 and
402.1005 for the compound, corresponding to both bromine isotopes. Further chemical character-
ization was performed by gas chromatography–mass spectrometry, liquid chromatography–diode
array detection and Fourier-transform infrared spectroscopy analyses. Finally, the structure was
confirmed by performing 1H-NMR and 13C-NMR spectroscopy. In vitro biological activity of bror-
phine was determined by a cell-based µ-opioid receptor activation assay, resulting in an EC50
of 30.9 nM (13.5 ng/mL) and an Emax of 209% relative to hydromorphone, confirming the high
potency and efficacy of this compound. In a serum sample of the patient, brorphine and a hydroxy-
metabolite were found using the LC–HRMS screening method. The presence of opioid activity in
the serum was also confirmed via the activity-based opioid screening assay. The occurrence of
brorphine is yet another example of how the illicit drug market is continuously evolving in an
attempt to escape international legislation. Its high potency poses a serious and imminent health
threat for any user.
Introduction
New psychoactive substances (NPS) intend to mimic the (pharma-
cological) effects of known prescription/controlled medications or
illicit drugs and are sold as (allegedly) legal alternatives. By the end
of 2019, 731 NPS had been notified to the European Early Warning
System (1, 2) and 950 to the United Nations Office on Drugs
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Figure 1. Structural similarities between (A) fentanyl, (B) benzylfentanyl and (C) the molecule discussed in this report, brorphine (1-(1-(1-(4-
bromophenyl)ethyl)piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one).
and Crime (UNODC) (3). Although the rate of appearance of
NPS detections in Europe seems to slow down, approximately 50
new substances are still reported annually. As NPS are typically
relatively cheap, easily available over the internet and often very
potent, many health problems are attributable to their use (1, 2). NPS
were involved in about 9.1% of the drug-related hospital emergency
presentations in Europe during the period 2014–2017. Although
cathinones and synthetic cannabinoids were the most prevalent, new
synthetic opioids have also made their entry in Europe (4).
A few years ago, new synthetic opioids primarily encompassed
analogs of the potent analgesic fentanyl, the latter having been asso-
ciated with tens of thousands of deaths in the United States during
the past few years (5–7). Whilst fentanyl, as well as its analogs,
remains present on the illicit market, the introduction of legislation
scheduling these substances has resulted in a marked decline in the
number of new “fentalogs” (8). Coinciding with the decrease in the
number of new fentanyl-related substances, other new synthetic opi-
oids have started to surface (9), including 2F-viminol, 2-Me-AP-237
and isotonitazene (10), the latter having been associated with several
hundreds of deaths in just a fewmonths in the United States (11, 12).
Brorphine [1-(1-(1-(4-bromophenyl)ethyl)piperidin-4-yl)-1,
3-dihydro-2H-benzo[d]imidazol-2-one] is a piperidine benzimida-
zolone derivative and could be considered a fentanyl analog
(Figure 1). However, it is not internationally scheduled and is
even outside the scope of generic legislations aiming at covering
fentanyl analogs (13, 14). Relatively little is known about this
novel NPS opioid. Already back in 1967, the opioid activity of
piperidine benzimidazolones was reported by Janssen (15). The syn-
thesis of a structural analog of brorphine, where p-bromophenyl
is substituted for an o-chlorophenyl group, was reported in the
1990s, in an attempt to develop an opioid-receptor-like 1 antagonist.
Despite its high binding affinity, this compound lacked selectivity
and antagonistic activity (16). Recently, the synthesis and in vitro
pharmacological characterization of brorphine were reported by
Kennedy et al. in the search for µ-opioid receptor (MOR) lig-
ands biased toward G protein signaling (17). Biased agonism at
MOR has received quite some interest, given the reported—but cur-
rently heavily questioned—association of β-arrestin signaling with
adverse events like respiratory depression and G protein signaling
with the desired (analgesic) effects of opioids (18–20). Interestingly,
in the report of Kennedy et al., brorphine was among the most
potent compounds, with a potency exceeding that of morphine (17).
Both the N-1-phenylethyl substituent and the bromo group in
para position were important for the high potency. Using two
distinct assays, monitoring either G protein signaling or β-arrestin
coupling, brorphine was found to be a full agonist, showing
some bias toward G protein signaling. Although no in vivo data
are available for brorphine itself, intraperitoneal injection of sev-
eral piperidine benzimidazolone derivatives demonstrated that this
class of compounds is capable of crossing the blood–brain barrier
(17, 21).
Brorphine has been mentioned on drug fora for a while and has
been reported to circulate in the American Midwest since the second
half of 2019 (22), although no formal reports on its identification
(either as a powder or in authentic cases) are available. At the time of
writing, we are not aware of any brorphine cases that were reported
to the UNODC Early Warning Advisory or the European Monitor-
ing Centre for Drugs and Drug Addiction. Therefore, in this article,
we report on the identification and full chemical characterization of
brorphine, sourced online and used by a patient querying admission
for detoxification. In addition, besides the unequivocal identification
of brorphine in serum samples from this patient, its MOR agonistic
activity was demonstrated, both as a powder and in the authentic
patient sample.
Case History
The patient, who provided written informed consent, was a 24-
year-old male who presented with withdrawal symptoms to the
emergency department, querying an admission for detoxification.
His complaints consisted of generalized pain, situated mainly in
the chest, abdomen and muscles. He had a normal blood pres-
sure with a tachycardia of 114/minute, oxygen saturation of 98%
and a temperature of 37.3◦C. He presented with confusion and
bradyphrenia, generalized weakness and cramping. On physical
examination, he was clammy and sweaty. A CT scan of the brain,
chest X-ray and ECG were all normal. Apart from a slightly ele-
vated gamma-glutamyltransferase of 111 U/L, there were no remark-
able abnormalities in the blood lab results. Anamnesis revealed
that he had a medical history of opioid misuse with the use of,
among others, the synthetic opioids 2-Me-AP-237 and intravenous
O-acetylmethylketobemidone (a derivative of the synthetic opioid
ketobemidone). He had an episode of abstinence of one year, up
to six months before presentation. One to two months before pre-
sentation, he started using brorphine orally four times a day, as
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presentation). He reported that the use of brorphine resulted in a
pretty strong effect, similar to oxycodone or fentanyl, with a result-
ing “high” that lasted quite long, and the development of tolerance.
He also reported to suffer from quite intense cravings after waking
up, with “cold turkey” more intense than heroin. His prescribed
medications consisted of sertraline, mirtazapine, methylphenidate
and enoxaparin. He reported no alcohol use.
Methods
Materials
All reagents used during the analyses were at least of high-
performance liquid chromatography (HPLC) grade. For nuclear
magnetic resonance (NMR) analysis, deuterated dimethyl sulfoxide
(DMSO-d6, 99.8%) was purchased from Eurisotop (Saint-Aubin,
France). Brorphine HCl (5 mg) reference standard (≥98% purity)
was obtained from Cayman Chemical Company (Ann Arbor, MI,
USA). Hydromorphone was purchased as hydrochloride salt from
Fagron (Nazareth, Belgium). Fentanyl was obtained from LGC
Chemicals (Wesel, Germany). Dulbecco’s modified Eagle’s medium
(GlutaMAX™), Opti-MEM® I reduced serum medium, penicillin-
streptomycin (5,000 U/mL) and amphotericin B (250 µg/mL) were
supplied by Thermo Fisher Scientific (Pittsburgh, PA, USA). Fetal
bovine serum (FBS) and poly-D-lysine were obtained from Sigma
Aldrich (Overijse, Belgium). The Nano-Glo® Live Cell Assay system
(containing theNano-Glo® Live Cell Substrate andNano-Glo® LCS
Dilution Buffer) was procured from Promega (Madison, WI, USA).
Description of the powder and sample preparation
The powder was obtained from the patient described earlier. As he
wanted to go into treatment, he delivered several unopened powder
sachets to the emergency physician. A larger, transparent resealable
plastic sachet (itself originally packed in an aluminum pouch) con-
tained two smaller powder sachets, one labeled as “Brorphine”, and
the other as “Etizolam”. These were obtained from a Dutch online
marketplace, only accessible by invitation, and had been shipped by
a courier service to the patient’s home. Both powder sachets were
labeled as “research chemical powder” and “not for human con-
sumption” (Supplementary Figure 1). Noteworthy is that the original
aluminum pouch also contained two A4 sheets of paper, one being
a disclaimer from the supplier that the product is for laboratory
research purposes only, and the other being a material safety data
sheet for etizolam.
The sample labeled as etizolam was indeed confirmed to contain
etizolam. This thienodiazepine derivative was the most frequently
seized benzodiazepine in Europe in 2017. It is particularly notorious
in Scotland, where it is often sold as a “street” benzodiazepine (1)
and was implicated in 57% of all drug-related deaths in 2018 (23).
Etizolam will not be discussed further in this report.
The brorphine powder was white and homogenous, as verified
by evaluating five independent samplings (CV<5.3%). The weight
of the brorphine sachet, including the powder, was 1.378 g. For
all chromatographic analyses, 3.7 mg of this powder was dissolved
in 3.7 mL methanol as stock solution and stored at−20◦C until
analysis. For NMR analysis, 7.5 mg of the powder was dissolved
in 0.75 mL DMSO-d6. For the determination of biological activity
at MOR, 3.93 mg of the powder was dissolved in 0.77 mL methanol
and further diluted for experiments.
Patient samples
Two serum samples, taken approximately 60 hours apart, were
available for (toxicological) analysis. The first sample was collected
at the emergency department and the second during hospitalization
in the psychiatric ward.
For liquid chromatography–high-resolution mass spectrometry
(LC–HRMS) screening and quantitative brorphine analysis, 50 µL
sample and 50 µL of internal standard solution (trimipramine-d3
500 ng/mL in water, routinely applied in our lab—no brorphine
isotope-labeled standard was available) were added to a tube and
mixed. After addition of 200 µL cold methanol/acetonitrile 50/50,
samples were stored for 30 minutes at −20◦C, subsequently shaken
for 5 minutes and centrifuged for 5 minutes at 16,162g. One hun-
dred microliters of the supernatant was transferred to HPLC vials,
and 10 µL was injected onto the ultra-high-performance liquid
chromatography (UHPLC) column.
For the activity-based assay, the sample preparation was kept
maximally similar to the LC–HRMS protocol. Here, 200 µL serum
was mixed with 800 µL cold methanol/acetonitrile 50/50. After
centrifugation, the supernatant was transferred to a glass tube and
evaporated at room temperature under a gentle stream of nitrogen
(Zymark Turbovap, Zymark Ltd, Cheshire, UK). The evaporated
extracts were then reconstituted in 100 µL OptiMEM® I reduced
serum medium, and 20 µL was used in the bio-assay. In a second
set of experiments, a standard curve for brorphine was generated by
spiking blank serum with different concentrations of the brorphine
reference standard (0.1–100,000 ng/mL).
LC–HRMS analysis
Both the powder and the patient samples were screened with the
same LC–HRMS method. The chromatographic separation was per-
formed using an Ultimate 3000 UHPLC system (Thermo Fisher
Scientific, Waltham, MA, USA) equipped with an Accucore phenyl-
hexyl column (100 mm length × 2.1-mm i.d., 2.6 µm particle size,
Thermo Fisher Scientific) at 40◦C. A gradient of mobile phase A
(2 mM ammonium formate, 0.1% formic acid (FA) in water) and B
(0.1% FA in methanol) with a flow rate of 0.5 mL/min was used for
elution of the compounds. Ten microliters of extract of the serum
samples or of a 1/100 dilution of the stock solution in methanol
was injected on the column. The HRMS system was a Q Exac-
tive (Thermo Fisher Scientific) with an electrospray ionization source
used in positive/negative switching ionization mode with a full scan
range of 70–1000 m/z. The full scan resolution was 35,000 (full
width at half maximum, FWHM) and the automatic gain control
(AGC) target was set at 1e6 and the maximum injection time at 120
msec. For screening, high-energy collisional dissociation experiments
were performed on compounds that matched the inclusion list (24)
and on the five most intense precursor ions using data-dependent
acquisition (DDA). Other settings for DDA were a resolution of
17,500 FWHM, AGC target of 1e5 with a maximum injection of
50 msec and an isolation window of 2.0 m/z (24).
A high-resolution accurate mass detection method was developed
for the quantification of brorphine using targeted selected ion mon-
itoring on the same Q Exactive system. A measuring window of
5 ppm (with an offset of 1 ppm) was set around the exact monoiso-
topic mass of 400.1020 m/z (and that of the internal standard) with
a mass resolution of 70,000 FWHM. The AGC target was set at 5e4
and the maximum injection time at 200 msec. The same UHPLC
conditions as in the screening method were used. Calibration curves
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lower limit of quantificationwas set at 1 ng/mL. Themethodwas val-
idated in terms of precision, accuracy, recovery and matrix effects.
Within- and between-run precision and within- and between-run
biases over all quality control levels were <14.5%. For details on
the method validation, see Supplementary Data.
Data were analyzed with Tracefinder 3.3 and FreeStyle 1.1
software (Thermo Fisher Scientific).
GC–MS analysis
One microliter of a one-fifth dilution of the stock solution in a
ToxiVial type A (Interchim, Montluçon, France) was injected on a
GC-2010 system coupled with a gas chromatography–mass spec-
trometry (GC–MS) QP2010 Plus mass spectrometer (Shimadzu,
Kyoto, Japan). Split injections were performed at an injection tem-
perature of 270◦C with helium as carrier gas at a constant flow rate
of 0.72 mL/min. A 12 m × 0.20-mm i.d. × 0.33µm HP-5ms col-
umn was used (Agilent, Santa Clara, CA, USA). The temperature
program started at 100◦C for 3 minutes, was ramped at 30◦C/min
to 310◦C, which was held for another 5 minutes, resulting in a total
run time of 15 minutes. The ion source temperature and interface
temperature were set at 200◦C and 220◦C, respectively. The MS
operated in scanning mode with a scanning range of 40–550 m/z
and an ionization energy of 70 eV.
UHPLC–DAD analysis
The chromatographic separation was achieved on an Acquity
UPLCTM system using an Acquity UPLCTM BEH C18 column (100
mm length × 2.1 mm i.d., 1.7 µm particle size), fitted with a Van-
guard Acquity BEH C18 guard column (5 mm length× 2.1 mm i.d.,
2.6 µm particle size) (Waters, Milford, MA, USA), kept at 35◦C.
Elution was achieved isocratically using 0.1% FA in water/0.1%
FA in acetonitrile 65/35% v/v as mobile phase. Ten microliters of a
one-tenth dilution of the stock solution was injected on the column.
Detection was done by diode array detection (DAD), monitoring
wavelengths between 190 and 400 nm with a slit of 0.5 µm and
resolution of 1.2 nm.
FT-IR spectroscopy analysis
The powder was analyzed using Fourier-transform infrared (FT-
IR) spectroscopy in reflectance mode on a Spectrum 2 photometer
(Perkin Elmer, Waltham, MA, USA). A small amount of the powder
was deposited directly on the crystal without any prior sample prepa-
ration. The IR spectrum was recorded in the range 4000–400 cm−1
with a spectral resolution of 4 cm−1. Spectral data were obtained
using the Spectrum Quant software (Perkin Elmer).
NMR analysis
NMRmeasurements were performed on a Bruker Avance Neo® 400
MHz spectrometer at 25◦C. Chemical shifts (δ) are reported in parts
per million, and spectra are referenced to the residual solvent peak
signal. Coupling constants are given in Hertz.
Determination of in vitro biological activity at MOR
The biological activity of brorphine at MOR was evaluated by
means of a previously reported, live cell-based MOR reporter assay
(20, 25). The employed assay monitors MOR activation via its
interactionwithβ-arrestin 2 (βarr2) using theNanoLuc Binary Tech-
nology® (Promega). Human embryonic kidney 293 T cells stably
expressing the MOR reporter system were cultured in Dulbecco’s
modified Eagle’s medium (GlutaMAX™) supplemented with 10%
heat-inactivated FBS, 100 IU/mL penicillin, 100 mg/L streptomycin
and 0.25 mg/L amphotericin B at 37◦C in a humidified atmosphere
containing 5% CO2. The stability of the cell line was routinely mon-
itored by flow cytometric analysis of co-expressed markers (20). One
day prior to the experiments, the cells were seeded on poly-D-lysine
coated 96-well plates at 5×104 cells/well. After overnight incuba-
tion, the cells were washed twice with Opti-MEM® I reduced serum
medium to remove remaining traces of FBS. Next, 90 µL Opti-
MEM® I and 25 µL Nano-Glo® Live Cell reagent were added to
the washed wells. The plate was subsequently placed into a TriS-
tar2 LB 942 multimode microplate reader (Berthold Technologies
GmbH & Co., Bad Wildbad, Germany). During an initial equi-
libration period (10–15 minutes), luminescence was continuously
monitored until stabilization of the signal. Twenty microliters of
each test compound (present as 6.75-fold concentrated stock solu-
tions in Opti-MEM®/MeOH) or, alternatively, of the reconstituted
serum extracts (cf. Section Methods—Patient samples) was added
per well before continuously monitoring luminescence for 120 min-
utes. Hydromorphone was used as a reference agonist (10), and
appropriate solvent controls were included. The results are presented
as mean area under the curve± standard error of mean (SEM),
obtained in three independent experiments (N=3), with duplicates
run for each concentration within an experiment. All results were
normalized to the maximum response of the reference compound
hydromorphone (arbitrarily set at 100%). Curve fitting and sta-
tistical analyses were performed using GraphPad Prism 8 software
(San Diego, CA, USA). Measures of potency (EC50) and efficacy
(Emax) were determined via nonlinear regression (four-parameter
logistic fit).
Results
LC–HRMS, GC–MS, HPLC–DAD and FT-IR
LC–HRMS analysis of the powder in full scan mode revealed a single
peak with a retention time of 5.48 minutes and an exact m/z value
of 400.1020. This matched with the exact mass of 400.1019 m/z
(mass deviation 0.25 ppm), assigned to single-protonated [M+H]
brorphine (C20H23BrN3O) in the HighResNPS library (26) and
reported by Kennedy et al. (17). The obtained full scan and
product ion spectra are shown in Figures 2A and B. The charac-
teristic bromine isotope pattern is obvious in the full scan spec-
trum, with obtained precursor ions of 400.1020 and 402.1005
m/z, corresponding to the 79Br and 81Br isotopes, respectively
(Figure 2A). The four main product ions had an m/z value of
84.0814 (matching with fragment corresponding to the piperidyl
ring (2,3,4,5-tetrahydropyridin-1-ium ion; C5H10N+)), 104.0625
(the phenylethyl moiety without the bromine atom (C8H8+)),
182.9805 (79Br) / 184.9786 (81Br) (the phenylethyl moiety with
the bromine atom (C8H8Br+)) and 218.1289 (the piperidine ben-
zimidazolone moiety (C12H16N3O+)) (27). Both the retention time
(difference <0.1 min) and the fragment ion spectrum (99.3% fit)
matched with those obtained for the reference standard (data not
shown).
GC–MS analysis revealed a single peak with a retention time
of 12.44 minutes (Figure 2C). A single peak, eluting at 1.05 min-
utes, and showing two absorption maxima, at 227 and 280 nm, was
obtained with LC–DAD analysis (Figure 2D). In both instances, the
retention time and MS or DAD spectrum matched those of the ana-
lytical standard (data not shown). No impurities (other peaks in the
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Figure 2. (A) HRMS full scan spectrum; (B) HRMS fragment ion spectrum; (C) GC–MS electron impact ionization spectrum; (D) HPLC–DAD spectrum; (E) FT-IR
spectrum of the brorphine powder with indication of the characteristic bands.
FT-IR analysis of the sample using attenuated total reflectance
revealed main absorbance peaks at 1676, 1482, 1374, 756 and
737 cm−1 (Figure 2E). The IR spectrum did not match any entry
in an in-house library.
NMR analysis
1H-NMR analysis was in complete agreement with published val-
ues (Figure 3A) (17). 13C-NMR analysis was performed for full
structural confirmation (Figure 3B). 1H-13C heteronuclear single
quantum coherence was performed to aid in structural assignment
(Supplementary Figure 2).
Determination of in vitro biological activity at MOR
The brorphine reference standard gave rise to a concentration-
dependent response in the MOR activation bio-assay (Figure 4),
allowing derivation of potency (EC50) and efficacy (Emax) data,
the latter relative to hydromorphone (Table I). The obtained
data show that, whereas brorphine is comparable to hydromor-
phone (the reference compound used in this assay) in terms
of potency, it is about twice as efficacious in activating MOR
(Emax 191–230%).
Interestingly, the activation profiles of the sourced powder and
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Figure 3. (A) 1H-NMR spectrum (400 MHz, DMSO-d6) δ: 1.31 (d, J=6.7 Hz, 3H, CH3), 1.59 (d, J=11.2 Hz, 1H, H-3pip/H-5pip), 1.66 (d, J=11.5 Hz, 1H, H-3pip/H-5pip),
1.98 (t, J=11.6 Hz, 1H, H-2pip/H-6pip), 2.07 (t, J=11.7 Hz, 1H, H-2pip/H-6pip), 2.24–2.40 (m, 2H, H-3pip/H-5pip), 2.87 (d, J=10.4 Hz, 1H, H-2pip/H-6pip), 3.06 (d, J=10.4
Hz, 1H, H-2pip/H-6pip), 3.55 (q, J=6.7 Hz, 1H, NCHPhe), 4.06 (tt, J=12.2 Hz, 4.1 Hz, 1H, H-4pip), 6.93–7.01 (m, 3H, H-5Benzimid, H-6Benzimid, H-7Benzimid), 7.20 (d,
J=6.5 Hz, 1H, H-4Benzimid), 7.33 (d, J=8.6 Hz, 2H, H-2Phe, H-6Phe), 7.53 (d, J=8.6 Hz, 2H, H-3Phe, H-5Phe), 10.81 (s, 1H, NH); (B) 13C-NMR spectrum (100 MHz,
DMSO-d6) δ: 18.7 (CH3), 28.85 (C-3pip/C-5pip), 28.90 (C-3pip/C-5pip), 49.1 (C-2pip/C-6pip), 49.7 (C-2pip/C-6pip), 50.3 (C-4pip), 62.5 (NCHPhe), 108.6 (C-4Benzimid), 108.7
(C-7Benzimid), 119.7 (C-4PheBr),120.3 (C-5Benzimid), 120.4 (C-6Benzimid), 128.3 (C-3aBenzimid), 129.3 (C-7aBenzimid), 129.6 (2C, C-2PheBr/C-6PheBr), 131.0 (2C, C-3PheBr/C-5PheBr),
143.0 (C-1PheBr), 153.7 (C-2).
(Figure 4). This, combined with the analytical data, indicates the
high purity of the obtained powder.
Patient samples
Two serum samples were available from the patient, col-
lected approximately 60 hours apart. Toxicological screening by
immunoassays and enzymatic methods of the initial serum sam-
ple for ethanol, benzodiazepines, opiates and GHB was negative.
Antidepressants (sertraline and mirtazapine, known medications of
the patient) and an atypical antipsychotic (risperidone) were found
in subtherapeutic ranges. In the second sample, trazodone and nor-
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Figure 4. Concentration-dependent interaction of MOR with βarr2 upon stimulation with the brorphine reference standard (circles), the obtained brorphine
powder (diamonds) and the reference agonist, hydromorphone (HM) (triangles). Data are shown as mean receptor activation±SEM (N=3), normalized to the
Emax of hydromorphone (=100%).
Table I. Values for Potency (EC50) and Efficacy (Emax), with 95% Confidence Intervals (CIs), as Obtained in the MOR Activation Assay
EC50 (ng/mL) EC50 (nM) Emax (%)
Hydromorphone 8.38 (4.26–18.9) 26.0 (13.3–58.6) 97.5 (86.9–114)
Brorphine (reference) 13.5 (8.94–20.0) 30.9 (20.5–45.7) 209 (191–230)
Brorphine (powder) 13.5 (7.36–22.3) – 199 (176–224)
neither of the samples could etizolam, O-acetylmethylketobemidone
or 2-Me-AP-237 be detected.
On the basis of the anamnesis and with the obtained exact
mass and product ions from the powder, the presence of bror-
phine was confirmed in both available serum samples. For both
samples, the retention time of brorphine in the LC–HRMS screen-
ing method matched that of the reference standard (i.e., within
0.1 minute). The obtained exact masses of both precursor and
fragment ions (taking into account the typical bromine isotope
pattern, with m/z 400.1029–402.1000 and 182.9810–184.9784,
respectively) matched those of the reference standard [mass devia-
tion < 3 ppm, matching the criterion of 10 ppm (24)] (Supplementary
Figures 3A and B). The obtained brorphine concentrations in the
first and second serum sample were 69.4 and 7.9 ng/mL, respec-
tively. In addition, a peak with a retention time of 4.79 minutes, an
exact mass of 416.0970 m/z and major product ions of 234.1238,
182.9805, 104.0625 and 84.0814 m/z was also found in the first
sample, suggesting the presence of a brorphine hydroxy-metabolite,
with the OH-group situated on the phenyl ring of the benzimida-
zolone moiety. Supplementary Figures 4A and B show the obtained
HRMS fragment ion spectrum for this metabolite for both the 79Br
isotope and the 81Br isotope. The fact that, after 60 hours, brorphine
was still detectable in the patient’s serum, suggests a long half-life.
This is in line with the patient’s subjective feeling.
The presence of opioid activity in the serum sample collected
upon admission of the patient was confirmed by the opioid recep-
tor activation assay: a signal clearly distinct from background was
observed (Figure 5). On the one hand, this demonstrates the bio-
assay’s potential to pick up opioid positive samples without prior
knowledge of the compound, which represents a great advantage
over other NPS screening methods (e.g., immunoassays). On the
other hand, these data allow some insight into the extent of opioid
activity present within the patient’s serum sample. More specifically,
based on the signals obtained from serum spiked with different con-
centrations of the brorphine reference standard, it could be derived
that in the admission serum sample an activity was present cor-
responding to a concentration between 10 and 20 ng/mL (23–46
nM) brorphine (Figure 6). The signal in the second serum sam-
ple, however, could not be considered unequivocally positive as the
bio-assay results were ambiguous and not reproducible. This is not
entirely unexpected as this sample was taken 60 hours after admis-
sion, and at that time point, no relevant opioid activity is expected
to be present anymore. This is also in line with the results from the
standard curve generated from spiking serum with different concen-
trations of brorphine, in which concentrations below 10 ng/mL gave
rise to ambiguous results (data not shown). This reliance on the
presence of a relevant concentration of a pharmacologically active
compound (i.e., a concentration still capable of activating MOR)
could be considered a limitation of the activity-based approach.
Discussion
This article reports on the identification and full chemical char-
acterization of an online sourced highly pure powder, identified
as brorphine. Brorphine is a novel potent synthetic opioid with a
piperidine benzimidazolone structure.
Using a wide array of techniques, including LC–HRMS, GC–MS,
LC–DAD, FT-IR and 1H- and 13C-NMR spectroscopy, the powder
obtained from a patient was unequivocally identified as brorphine.
The in vitro activity of brorphine at MOR was evaluated using
a previously reported, live cell-based assay (20, 25). The efficacy
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Figure 5. Activation profile (relative luciferase units (RLU) in function of time) observed in the MOR activation assay used for activity-based screening for opioids
in the patient’s serum samples.
Figure 6. “Activity equivalents” plot (relative luciferase units (RLU) in function of time), showing that the opioid activity found in the patient’s serum sample is
equivalent to a serum concentration between 10–20 ng/mL brorphine, 5–25 ng/mL hydromorphone (HM) or 0.5–2.5 ng/mL fentanyl. The patient sample and the
brorphine-spiked serum samples were fully processed (see Materials and Methods). To eliminate potential differences in recovery, HM and fentanyl were spiked
post-extraction and corresponding serum concentrations were calculated taking into account the different dilution steps during sample preparation.
reference agonist hydromorphone (Emax =97.5%), indicating
potentially higher levels of opioid effects with brorphine. With an
EC50 value of 30.9 nM (95% confidence interval (CI) 20.5–45.7 nM)
(Table I), the potency of this emerging synthetic opioid approaches
that of the potent analgesic fentanyl (18.7 nM; 95% CI 15.0–
23.3 nM) (20). Kennedy et al. used a different βarr2 recruitment
assay, a commercially available β-galactosidase-fragment comple-
mentation assay (PathHunter®, DiscoverX), to evaluate brorphine’s
βarr2 recruitment potential to human MOR, readily pointing out
the high potency of brorphine (EC50 182±42 nM) within their set
of tested compounds (17). The difference in absolute EC50 values
can be attributed to the different experimental set-ups, hampering
easy comparison of the results. The same study also investigated
the capability of brorphine to activate G protein signaling using a
35S-GTPyS binding assay in membranes from CHO-K1 cells
expressing human MOR (EC50 4.8±0.41 nM). The authors found
that brorphine showed a certain degree of bias toward activating
the G protein pathway (17). However, the findings of the βarr2
recruitment assay reported here, combined with those of a miniGi
recruitment assay reported elsewhere (28), do not support this pur-
ported bias toward the G protein pathway. More studies—including
evaluation in vivo—are needed to further clarify this.
Brorphine can be considered a substituted analogue of benzylfen-
tanyl, in which the acyl group is part of a closed ring structure
(Figure 1). We previously found that various substituted benzylfen-
tanyls activate MOR to only a very limited extent, with Emax
values of less than 10% compared to hydromorphone. In stark
contrast to brorphine, the potencies of these compounds were in
the high nM to µM range (29). Furthermore, as opposed to these
benzylfentanyls, brorphine is currently not covered by generic legis-
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This is also the first report on the identification of brorphine in
an authentic biological sample. Apart from the unequivocal iden-
tification of brorphine in two serum samples via LC–HRMS, the
use of a MOR activation assay also revealed the presence of opi-
oid activity in one serum sample. The employed assay monitors the
total MOR activity present in the patient sample, i.e., the activ-
ity conferred by brorphine, as well as by its metabolite(s). At this
point, there is no information as to whether brorphine metabolites
(such as the hydroxy-metabolite found here) have (relevant) opioid
activity. The opioid activity scored by the bio-assay indicated a bror-
phine serum concentration between 10 and 20 ng/mL (23–46 nM),
whereas the analytical concentration was 69.4 ng/mL (159 nM).
Both serum concentrations lie in the lower (i.e., non-linear) part of
the concentration-response curve of brorphine spiked in serum (data
not shown), suggesting the applicability of the bio-assay to serve as
a semiquantitative tool, as also recently demonstrated for synthetic
cannabinoid receptor agonists (30). Another advantage of being able
to assess total MOR activity is that this approach also allows to
make comparative statements versus a reference compound, here
hydromorphone. Hence, the activity can be expressed as an “activ-
ity equivalent”. More specifically, the activity present in the extract
of the patient admission sample lay within the range observed for
extracts from serum samples spiked with 10–20 ng/mL brorphine
(Figure 6, dashed lines). Taking into account the different dilution
steps during the sample preparation, this would be equivalent to
the activity exerted by roughly 5–25 ng/mL (16–78 nM) hydromor-
phone or 0.5–2.5 ng/mL (1.5–7.4 nM) fentanyl in serum (Figure 6).
Although in the context of opioid users the aspect of potential toler-
ance greatly hampers unequivocal interpretation, this approach does
provide insight into whether the MOR activity present in a patient’s
sample is high or not. In the current case, we can conclude that a
high opioid activity was present. Although in vitro pharmacological
characterization may lead to some guidance on anticipated potency,
the eventual in vivo effect is determined by many factors, amongst
which bioavailability, intrinsic potency (at distinct signaling path-
ways), metabolic stability, potential conversion to active metabolites
and penetration through the blood brain barrier. In the context of
opioid users, the aspect of potential tolerance also plays an impor-
tant role. The patient from this case had a known recent history of
opioid misuse and presented with withdrawal symptoms to the emer-
gency department, meaning that a certain degree of opioid tolerance
can be expected. The fact that he was conscious upon presentation
at the emergency department, despite having high opioid activity in
his blood, is in line with this.
Moreover, the fact that the MOR activation assay was able to
find a signal in the patient sample further underscores the potential
of activity-based screening. The general toxicology screening was
negative, and if there would not have been information about the
potential presence of brorphine in the patient’s sample, this positiv-
ity would undoubtedly have been missed, given the novelty of this
compound. In contrast, as long as there is relevant activity present
within a sample, activity-based screening will allow to determine the
presence of any (known or unknown) opioid, thereby serving as a
universal non-biased approach.
In conclusion, this study presents the first identification and full
chemical characterization of brorphine, an emerging synthetic opi-
oid with a piperidine benzimidazolone structure. The identification
of brorphine has not been previously reported, neither in pow-
der form nor in biological samples. Along with the demonstration
that brorphine acts as a strong MOR agonist, the fact that a large
amount of powder was obtained, corresponding to many doses,
is a cause of great concern. Should use of this compound become
more widespread, we consider it likely that new cases, including
fatalities, will emerge, as was the case for another recently emerg-
ing opioid, isotonitazene (10–12). Very recent data from the US
(A. Krotulski, D. Papsun, personal communication) indeed point
at fatalities with involvement of brorphine. Within the dynamic
landscape of NPS, the high potency and efficacy of brorphine once
again stress the importance of closely monitoring every new drug on
the block.
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